- Conditions
- Biliary Atresia
- Interventions
- Odevixibat
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NAFLD, NASH
- Interventions
- Elobixibat, Placebo oral tablet
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Canoga Park, California • Rialto, California • Colorado Springs, Colorado + 7 more
- Conditions
- Healthy Volunteers
- Interventions
- A4250
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Constipation, Chronic Constipation
- Interventions
- A3309
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Biliary Atresia
- Interventions
- Odevixibat, Placebo
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Up to 111 Days
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 25 more
- Conditions
- Progressive Familial Intrahepatic Cholestasis
- Interventions
- Odevixibat
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alagille Syndrome
- Interventions
- Odevixibat, Placebo
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
- Conditions
- Alagille Syndrome
- Interventions
- Odevixibat
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 14 more
- Conditions
- PFIC1, PFIC2
- Interventions
- A4250 (odevixibat), Placebo
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Progressive Familial Intrahepatic Cholestasis
- Interventions
- A4250 (odevixibat)
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- 0 Months to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more